NEW YORK--(BUSINESS WIRE)--
Bragar Eagel & Squire, P.C. is investigating potential claims against Psychemedics Corporation (NASDAQ:PMD) concerning possible violations of the federal securities laws.
On January 31, 2017, news reports revealed that Psychemedics’s local representative, Psychemedics Brasil Exames Toxicologicos Ltda., was ordered to compensate Omega Laboratories, Inc. USA for losses caused by anticompetitive practices used for the purpose of “preventing other companies from accessing (the) market.” The ruling notes that Psychemedics used “cartel practices,” in an attempt to form a drug testing monopoly which included unenforceable and exclusive contracts with collection sites, “all with a view to limit the entry and operation of new companies in the market.” Following this news, Psychemedics shares declined $6.75 per share on January 31, 2017 to close at $18.87.
If you purchased or otherwise acquired Psychemedics securities and suffered a loss, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact J. Brandon Walker, Esq. by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Psychemedics Corporation, please go to www.bespc.com/psychemedics-corporation. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170131006476/en/
